Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 11, 2016, Pages 1915-1925

  Palmer, Jeanne ^a   McCune, Jeannine S ^b   Perales, Miguel Angel ^c   Marks, David ^d   Bubalo, Joseph ^e   Mohty, Mohamad ^f   Wingard, John R ^g   Paci, Angelo ^h   Hassan, Moustapha ⁱ   Bredeson, Christopher ^j   Pidala, Joseph ^k   Shah, Nina ^l   Shaughnessy, Paul ^m   Majhail, Navneet ⁿ   Schriber, Jeff ^o   Savani, Bipin N ^p   Carpenter, Paul A ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BRISTOL ROYAL INFIRMARY   (United Kingdom)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f HÔPITAL SAINT ANTOINE   (France)

^g UNIVERSITY OF FLORIDA   (United States)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^k H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m Pediatric Blood and Marrow Transplantation   (United States)

ⁿ LERNER RESEARCH INSTITUTE   (United States)

^o Cancer Transplant Institute   (United States)

^p VANDERBILT INGRAM CANCER CENTER   (United States)

more..

Author keywords

Busulfan; Hematopoietic cell transplantation; Pharmacokinetics; Precision medicine; Therapeutic drug monitoring

Indexed keywords

BUSULFAN; MYELOABLATIVE AGENT;

ADULT; CHILD; CLINICAL OUTCOME; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; GENETIC POLYMORPHISM; GRAFT REJECTION; GROUPS BY AGE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER DISEASE; MEDICAL SOCIETY; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; REVIEW; THERAPEUTIC INDEX; TRANSPLANTATION CONDITIONING; TREATMENT INDICATION; VOLUME OF DISTRIBUTION; PROCEDURES;

BUSULFAN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELOABLATIVE AGONISTS; PRECISION MEDICINE; TRANSPLANTATION CONDITIONING;

EID: 84992346042     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2016.07.013     Document Type: Review

References (118)

1. 1 Louis, J., Treatment of polycythemia vera with busulfan (myleran). JAMA 168 (1958), 1880–1882.
2. 2 Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. “Leukemia and Hematosarcoma” Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer 44 (1981), 75–80.
3. 3 Shvidel, L., Sigler, E., Haran, M., et al. Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia. Leukemia 21 (2007), 2071–2072.
4. 4 Santos, G.W., Tutschka, P.J., Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia. J Natl Cancer Inst 53 (1974), 1781–1785.
5. 5 Santos, G.W., Tutschka, P.J., Effect of busulfan on antibody production and skin allograft survival in the rat. J Natl Cancer Inst 53 (1974), 1775–1780.
6. 6 Santos, G.W., Tutschka, P.J., Brookmeyer, R., et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309 (1983), 1347–1353.
7. 7 Elfenbein, G.J., Brogaonkar, D.S., Bias, W.B., et al. Cytogenetic evidence for recurrence of acute myelogenous leukemia after allogeneic bone marrow transplantation in donor hematopoietic cells. Blood 52 (1978), 627–636.
8. 8 Clift, R.A., Buckner, C.D., Thomas, E.D., et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84 (1994), 2036–2043.
9. 9 Beschorner, W.E., Pino, J., Boitnott, J.K., Tutschka, P.J., Santos, G.W., Pathology of the liver with bone marrow transplantation. Effects of busulfan, carmustine, acute graft-versus-host disease, and cytomegalovirus infection. Am J Pathol 99 (1980), 369–385.
10. 10 Jones, R., Nieto, Y., Rizzo, J.D., et al. The evolution of the evidence-based review: evaluating the science enhances the art of medicine–statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 11 (2005), 819–822.
11. 11 Grochow, L.B., Jones, R.J., Brundrett, R.B., et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25 (1989), 55–61.
12. 12 Dix, S.P., Wingard, J.R., Mullins, R.E., et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17 (1996), 225–230.
13. 13 Slattery, J.T., Sanders, J.E., Buckner, C.D., et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16 (1995), 31–42.
14. 14 McCune, J.S., Gibbs, J.P., Slattery, J.T., Plasma concentration monitoring of busulfan: does it improve clinical outcome?. Clin Pharmacokinet 39 (2000), 155–165.
15. 15 Grochow, L.B., Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20:4 suppl 4 (1993), 18–25.
16. 16 Bolinger, A.M., Zangwill, A.B., Slattery, J.T., et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 28 (2001), 1013–1018.
17. 17 Slattery, J.T., Clift, R.A., Buckner, C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89 (1997), 3055–3060.
18. 18 Radich, J.P., Gooley, T., Bensinger, W., et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102 (2003), 31–35.
19. 19 Baker, K.S., Bostrom, B., DeFor, T., Ramsay, N.K., Woods, W.G., Blazar, B.R., Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia. Bone Marrow Transplant 26 (2000), 607–614.
20. 20 McCune, J.S., Gooley, T., Gibbs, J.P., et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 30 (2002), 167–173.
21. 21 McCune, J.S., Baker, K.S., Blough, D.K., et al. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. J Clin Pharmacol 53 (2013), 264–275.
22. 22 Lee, J.W., Kang, H.J., Lee, S.H., et al. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Biol Blood Marrow Transplant 18 (2012), 944–950.
23. 23 Bonifazi, F., Storci, G., Bandini, G., et al. Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation. Haematologica 99 (2014), 172–179.
24. 24 Gaziev, J., Nguyen, L., Puozzo, C., et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood 115 (2010), 4597–4604.
25. 25 Malär, R., Sjöö, F., Rentsch, K., Hassan, M., Güngör, T., Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr Transplant 15 (2011), 580–588.
26. 26 Pawlowska, A.B., Blazar, B.R., Angelucci, E., Baronciani, D., Shu, X.O., Bostrom, B., Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 20 (1997), 915–920.
27. 27 Ansari, M., Théoret, Y., Rezgui, M.A., et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Ther Drug Monit 36 (2014), 93–99.
28. 28 Russell, J.A., Kangarloo, S.B., Williamson, T., et al. Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation. Biol Blood Marrow Transplant 19 (2013), 1381–1386.
29. 29 Chen, Y.-B., Coughlin, E., Kennedy, K.F., et al. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant 19 (2013), 981–987.
30. 30 Ben-Barouch, S., Cohen, O., Vidal, L., Avivi, I., Ram, R., Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis. Bone Marrow Transplant 51 (2016), 232–240.
31. 31 Magenau, J., Tobai, H., Pawarode, A., et al. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood 118 (2011), 4258–4264.
32. 32 El-Jawahri, A., Li, S., Ballen, K.K., et al. Phase II trial of reduced-intensity busulfan/clofarabine conditioning with allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia,myelodysplastic syndromes, and acute lymphoid leukemia. Biol Blood Marrow Transplant 22 (2016), 80–85.
33. 33 Andersson, B.S., Bhagwatwar, H.P., Chow, D.S., Parenteral busulfan for treatment of malignant disease US 5559148 A. Available at: http://www.google.com/patents/US5559148, 1996 Accessed July 15, 2016.
34. 34 IV Busulfex Product Information. Available at: http://otsuka-us.com/media/static/IVBusulfex.PI.pdf, 2015 Accessed February 10, 2016.
35. 35 Giralt, S., Ballen, K., Rizzo, D., et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 15 (2009), 367–369.
36. 36 Small, T.N., Young, J.W., Castro-Malaspina, H., et al. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant 13 (2007), 235–244.
37. 37 Nieto, Y., Valdez, B.C., Thall, P.F., et al. Vorinostat combined with high-dose gemcitabine, busulfan, and melphalan with autologous stem cell transplantation in patients with refractory lymphomas. Biol Blood Marrow Transplant 21 (2015), 1914–1920.
38. 38 Rezvani, A.R., McCune, J.S., Storer, B.E., et al. Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes. Biol Blood Marrow Transplant 19 (2013), 1033–1039.
39. 39 Pidala, J., Lee, S.J., Quinn, G., Jim, H., Kim, J., Anasetti, C., Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 17 (2011), 1528–1536.
40. 40 Deeg, H.J., Storer, B., Slattery, J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100 (2002), 1201–1207.
41. 41 Hassan, M., Ljungman, P., Ringden, O., et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 25 (2000), 915–924.
42. 42 Bartelink, I.H., Bredius, R.G., Belitser, S.V., et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant 15 (2009), 231–241.
43. 43 Veal, G.J., Nguyen, L., Paci, A., et al. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. Eur J Cancer 48 (2012), 3063–3072.
44. 44 Mårtensson, T., Priftakis, P., Casswall, T., et al. Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning. Pediatr Transplant 17 (2013), 285–293.
45. 45 Deeg, H.J., Storer, B.E., Boeckh, M., et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 12 (2006), 573–584.
46. 46 Bornhauser, M., Storer, B., Slattery, J.T., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 102 (2003), 820–826.
47. 47 McCune, J.S., Woodahl, E.L., Furlong, T., et al. A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. Cancer Chemother Pharmacol 69 (2012), 263–272.
48. 48 Copelan, E.A., Hamilton, B.K., Avalos, B., et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood 122 (2013), 3863–3870.
49. 49 Ayala, E., Figueroa, J., Perkins, J., et al. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 15 (2015), 335–340.
50. 50 Parmar, S., Rondon, G., de Lima, M., et al. Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. Biol Blood Marrow Transplant 19 (2013), 474–480.
51. 51 Andersson, B.S., Valdez, B.C., de Lima, M., et al. Clofarabine +/- fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 17 (2011), 893–900.
52. 52 Kebriaei, P., Basset, R., Ledesma, C., et al. Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18 (2012), 1819–1826.
53. 53 Zhang, H., Graiser, M., Hutcherson, D.A., et al. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 18 (2012), 1287–1294.
54. 54 Chen, Y.B., Li, S., Fisher, D.C., et al. Phase II trial of tandem high-dose chemotherapy with autologous stem cell transplantation followed by reduced-intensity allogeneic stem cell transplantation for patients with high-risk lymphoma. Biol Blood Marrow Transplant 21 (2015), 1583–1588.
55. 55 Rambaldi, A., Grassi, A., Masciulli, A., et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 16 (2015), 1525–1536.
56. 56 Field, T., Perkins, J., Alsina, M., et al. Busulfan area-under-the-curve finding study within a busulfan/fludarabine (BuFlu) conditioning regimen before allogeneic hematopoietic cell transplantation (HCT). Blood, 108, 2006 [Abstract 2939].
57. 57 O'Donnell, P.V., Woolfrey, A.E., Storer, B., et al. Effect of substituting fludarabine and thymoglobulin for cyclophosphamide in busulfan-based conditioning Regimens on T-cell chimerism and outcomes after allogeneic hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant 14 (2007), 112–113.
58. 58 Perkins, J.B., Kim, J., Anasetti, C., et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 18 (2012), 1099–1107.
59. 59 Pidala, J., Roman-Diaz, J., Kim, J., et al. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. Int J Hematol 93 (2011), 206–212.
60. 60 O'Donnell, P.H., Artz, A.S., Undevia, S.D., et al. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma 51 (2010), 2240–2249.
61. 61 Geddes, M., Kangarloo, S.B., Naveed, F., et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 14 (2008), 220–228.
62. 62 Madden, T., de Lima, M., Thapar, N., et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 13 (2007), 56–64.
63. 63 Kashyap, A., Wingard, J., Cagnoni, P., et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 8 (2002), 493–500.
64. 64 Lee, J.H., Choi, S.J., Lee, J.H., et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 84 (2005), 321–330.
65. 65 Dean, R.M., Pohlman, B., Sweetenham, J.W., et al. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. Br J Haematol 148 (2010), 226–234.
66. 66 Pidala, J., Kim, J., Anasetti, C., et al. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol, 3, 2010, 36.
67. 67 Sobecks, R.M., Rybicki, L., Yurch, M., et al. Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS. Bone Marrow Transplant 47 (2012), 633–638.
68. 68 Lombardi, L.R., Kanakry, C.G., Zahurak, M., et al. Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leuk Lymphoma 57 (2016), 666–675.
69. 69 Mamlouk, K., Saracino, G., Berryman, R.B., et al. Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring. Bone Marrow Transplant 35 (2005), 747–754.
70. 70 Aggarwal, C., Gupta, S., Vaughan, W.P., et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 12 (2006), 770–777.
71. 71 Kato, M., Takahashi, Y., Tomizawa, D., et al. Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia. Biol Blood Marrow Transplant 19 (2013), 1690–1694.
72. 72 Bredeson, C., Intravenous versus oral busulfan-based conditioning for pediatric allogeneic hematopoietic cell transplantations: did the pendulum swing too far, too fast?. Biol Blood Marrow Transplant 19 (2013), 1657–1658.
73. 73 Flowers, C.R., Costa, L.J., Pasquini, M.C., et al. Efficacy of pharmacokinetics-directed busulfan, cyclophosphamide, and etoposide conditioning and autologous stem cell transplantation for lymphoma: comparison of a multicenter phase II study and CIBMTR outcomes. Biol Blood Marrow Transplant 22 (2016), 1197–1205.
74. 74 Slattery, J.T., Risler, L.J., Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 20 (1998), 543–549.
75. 75 Salinger, D.H., Vicini, P., Blough, D.K., O'Donnell, P.V., Pawlikowski, M.A., McCune, J.S., Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration. J Clin Pharmacol 50 (2010), 1292–1300.
76. 76 Nguyen, L., Fuller, D., Lennon, S., Leger, F., Puozzo, C.I.V., busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 33 (2004), 979–987.
77. 77 Booth, B.P., Rahman, A., Dagher, R., et al. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol 47 (2007), 101–111.
78. 78 McCune, J.S., Bemer, M.J., Barrett, J.S., Scott Baker, K., Gamis, A.S., Holford, N.H., Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res 20 (2014), 754–763.
79. 79 AMA, Payment allowance limits for Medicare Part B drugs. Available at: https://www.cms.gov/apps/ama/license.asp?file=/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/Downloads/2016-July-ASP-Pricing-File.zip Accessed July 15, 2016.
80. 80 AMA, Quantitative assay, drug. CPT code 80299. 2016 CPT-4 and HCPCS Codes Subject to CLIA Edits; Available at: https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/SubjecttoCLIA.pdf Accessed July 15, 2016.
81. 81 Michel, G., Valteau-Couanet, D., Gentet, J.C., et al. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer 58 (2012), 90–97.
82. 82 Yeh, R.F., Pawlikowski, M.A., Blough, D.K., et al. Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 18 (2012), 265–272.
83. 83 de Lima, M., Couriel, D., Thall, P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104 (2004), 857–864.
84. 84 Bubalo, J., Carpenter, P.A., Majhail, N., et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee. Biol Blood Marrow Transplant 20 (2014), 600–616.
85. 85 Li, C., Wu, X., Feng, X., et al. A novel conditioning regimen improves outcomes in beta-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood 120 (2012), 3875–3881.
86. 86 Shea, T., Walko, C., Chung, Y., et al. Phase I/II trial of dose escalated busulfan delivered by prolonged continuous infusion in allogeneic transplant patients. Biol Blood Marrow Transplant 21 (2015), 2129–2135.
87. 87 Ryu, S.G., Lee, J.H., Choi, S.J., et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant 13 (2007), 1095–1105.
88. 88 Mellgren, K., Nilsson, C., Fasth, A., et al. Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen. Bone Marrow Transplant 41 (2007), 621–625.
89. 89 Ward, J., Kletzel, M., Duerst, R., et al. Single daily busulfan dosing for infants with nonmalignant diseases undergoing reduced-intensity conditioning for allogeneic hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 21 (2015), 1612–1621.
90. 90 Tse, W.T., Duerst, R., Schneiderman, J., Chaudhury, S., Jacobsohn, D., Kletzel, M., Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. Bone Marrow Transplant 44 (2009), 145–156.
91. 91 Kletzel, M., Jacobsohn, D., Duerst, R., Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 12 (2006), 472–479.
92. 92 Pasquini, M.C., Le-Rademacher, J., Zhu, X., et al. Intravenous busulfan-based myeloablative conditioning regimens prior to hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 22 (2016), 1424–1430.
93. 93 US DHHS, FDA CDER, CBER, FDA guidance for industry on population pharmacokinetics. February, 1999.
94. 94 Younis, I.R., Elliott, M., Peer, C.J., et al. Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1. J Pharmacol Exp Ther 327 (2008), 770–776.
95. 95 Peer, C.J., Younis, I.R., Leonard, S.S., et al. Glutathione conjugation of busulfan produces a hydroxyl radical-trapping dehydroalanine metabolite. Xenobiotica 42 (2012), 1170–1177.
96. 96 Gibbs, J.P., Murray, G., Risler, L., Chien, J.Y., Dev, R., Slattery, J.T., Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 57 (1997), 5509–5516.
97. 97 Versace, F., Uppugunduri, C.R., Krajinovic, M., et al. A novel method for quantification of sulfolane (a metabolite of busulfan) in plasma by gas chromatography-tandem mass spectrometry. Anal Bioanal Chem 404 (2012), 1831–1838.
98. 98 El-Serafi, I., Terelius, Y., Twelkmeyer, B., Hagbjork, A.L., Hassan, Z., Hassan, M., Gas chromatographic-mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci 913-914 (2013), 98–105.
99. 99 Czerwinski, M., Gibbs, J.P., Slattery, J.T., Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 24 (1996), 1015–1019.
100. 100 Bredschneider, M., Klein, K., Murdter, T.E., et al. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin Pharmacol Ther 71 (2002), 479–487.
101. 101 Marr, K.A., Crippa, F., Leisenring, W., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103 (2004), 1527–1533.
102. 102 de Castro, F.A., Lanchote, V.L., Voltarelli, J.C., Colturato, V.A.R., Simões, B.P., Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. J Clin Pharmacol 53 (2013), 1205–1211.
103. 103 Hassan, M., Svensson, J.O., Nilsson, C., et al. Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy. Ther Drug Monit 22 (2000), 383–385.
104. 104 Buggia, I., Zecca, M., Alessandrino, E.P., et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 16:4A (1996), 2083–2088.
105. 105 Nilsson, C., Aschan, J., Hentschke, P., Ringden, O., Ljungman, P., Hassan, M., The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 31 (2003), 429–435.
106. 106 Hassan, M., Öberg, G., Björkholm, M., Wallin, I., Lindgren, M., Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 33 (1993), 181–186.
107. 107 Kangarloo, S.B., Naveed, F., Ng, E.S.M., et al. Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing. Biol Blood Marrow Transplant 18 (2012), 295–301.
108. 108 Beumer, J., Owzar, K., Lewis, L., et al. Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an Alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74 (2014), 927–938.
109. 109 Paci, A., Vassal, G., Moshous, D., et al. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. Ther Drug Monit 34 (2012), 198–208.
110. 110 Sureda, A., Perez de Oteyza, J., Garcia Larana, J., Odriozola, J., High-dose busulfan and seizures. Ann Intern Med 111 (1989), 543–544.
111. 111 Eberly, A.L., Anderson, G.D., Bubalo, J.S., McCune, J.S., Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 28 (2008), 1502–1510.
112. 112 Soni, S., Skeens, M., Termuhlen, A.M., Bajwa, R.P., Gross, T.G., Pai, V., Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer 59 (2012), 762–764.
113. 113 Uppugunduri, C.R.S., Rezgui, M.A., Diaz, P.H., et al. The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics J 14 (2014), 263–271.
114. 114 CIBMTR, Study# RT15-02: Association of anti-epileptic medication with outcomes after conditioning with targeted busulfan followed by cyclophosphamide before allogeneic hematopoietic cell transplantation. Available at: https://www.cibmtr.org/Studies/Observational/StudyLists/pages/ObservationalStudies.aspx?OSTID=a0IE00000059lm9MAA Accessed June 3, 2016.
115. 115 Russell, J.A., Tran, H.T., Quinlan, D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 8 (2002), 468–476.
116. 116 Gulbis, A.M., Culotta, K.S., Jones, R.B., Andersson, B.S., Busulfan and metronidazole: an often forgotten but significant drug interaction. Ann Pharmacother, 45, 2011, e39.
117. 117 Sweiss, K., Patel, P., Rondelli, D., Deferasirox increases BU blood concentrations. Bone Marrow Transplant 47 (2012), 315–316.
118. 118 University of Washington Metabolism and Transport Drug Interaction Database. University of Washington 1999-2016; Available at: https://www.druginteractioninfo.org/ Accessed: March 17, 2016.